Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03233867 · ClinicalTrials.gov registry record
A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations
A clinical trial, sponsored by Aevi Genomic Medicine, LLC, a Cerecor company.
- Completed
- Registry status
- 2,503
- Enrollment target
NCT03233867: Completed study, sponsored by Aevi Genomic Medicine, LLC, a Cerecor company.
NCT03233867 is a clinical trial that has completed, run by Aevi Genomic Medicine, LLC, a Cerecor company. The registered enrollment target is 2,503 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03233867 has completed, sponsored by Aevi Genomic Medicine, LLC, a Cerecor company.
- COMPLETED
- Registry status
- 2,503 participants
- Enrollment target
Study Summary
This is a non-interventional study in children and adolescents (ages 6-17 years) with attention deficit hyperactivity disorder (ADHD) to assess CNVs in specific genes involved in glutamatergic signaling and neuronal connectivity. The screening in this study will be conducted through a combination of online and site performed activities.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,503 participants |
| Start Date | 2017-08-14 |
| Est. Completion | 2018-08-03 |
What the finished NCT03233867 record still lists
NCT03233867 is an observational study that tracks outcomes without assigning an intervention. Its 2,503 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT03233867 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03233867 about?
NCT03233867 is a clinical study titled "A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations". This is a non-interventional study in children and adolescents (ages 6-17 years) with attention deficit hyperactivity disorder (ADHD) to assess CNVs in specific genes involved in glutamatergic signaling and neuronal connectivity. The screening in this study will be conducted through a combination of...
What is the current status of trial NCT03233867?
This trial is currently completed. The enrollment target is 2,503 participants. The study started on 2017-08-14. Estimated completion is 2018-08-03.
Who is sponsoring clinical trial NCT03233867?
This trial is sponsored by Aevi Genomic Medicine, LLC, a Cerecor company, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
- NCT01904188 · 2,500 participants
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
- NCT02257229 · 2,500 participants
Prospective Evaluation of Treatment for Clubfoot
- NCT02530658 · 2,500 participants
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI